Annual Drug Patent Expirations for PROMACTA Promacta is a drug marketed by Novartis Pharms Corp and is included in two NDAs. It is available from two suppliers. There are fourteen…
Recent successful drug launches indicate a trend toward more specialized, high-priced drugs that treat less-common medical conditions.
Annual Drug Patent Expirations for QBREXZA Qbrexza is a drug marketed by Dermira Inc and is included in one NDA. It is available from one supplier. There are eight patents…
Pharmaceutical Formulary Management: Anticipating generic entry, identifying first generic entrants, and projecting drug price drops
0
Pharmaceutical formulary managers have a pressing need to manage their formulary budgets. Anticipating when drugs will face loss-of-exclusivity — when their key patents will expire — is an essential first-step…
Measuring the knowledge translation and convergence in pharmaceutical innovation by funding-science-technology-innovation linkages analysis
0
This paper was originally published by Jian Du, Peixin Li, Qianying Guo, and Xiaoli Tang at Journal of Informetrics Volume 13, Issue 1, February 2019, Pages 132-148 under a a Creative Commons license.…
Prescription drugs are expensive to develop, and many intermediaries stand between patients and drug makers. Here’s where the money goes.
Annual Drug Patent Expirations for STARLIX Starlix is a drug marketed by Novartis and is included in one NDA. It is available from one supplier. There are two patents protecting…
Businessman and investor Mark Cuban is probably best known as the owner of the Dallas Mavericks and as an investor on the reality television series Shark Tank. His business and…
Anticipate the Future Global biopharmaceutical markets face constant change. To remain competitive you need to anticipate what’s next. We understand and work together with you to help you make better…
Partner With DrugPatentWatch Become a Data Integration Partner DrugPatentWatch’s Data Integration Program is for companies that want to better serve their clients by building an integration between their technology and…